73.96
price down icon16.30%   -14.40
after-market After Hours: 76.64 2.68 +3.62%
loading
Corcept Therapeutics Inc stock is traded at $73.96, with a volume of 2.28M. It is down -16.30% in the last 24 hours and up +3.27% over the past month. Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$88.36
Open:
$87.54
24h Volume:
2.28M
Relative Volume:
2.78
Market Cap:
$7.79B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
58.70
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-16.10%
1M Performance:
+3.27%
6M Performance:
+9.20%
1Y Performance:
+63.45%
1-Day Range:
Value
$73.12
$87.54
1-Week Range:
Value
$73.12
$91.00
52-Week Range:
Value
$42.01
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
Name
Corcept Therapeutics Inc
Name
Phone
650.688.8803
Name
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
Employee
500
Name
Twitter
Name
Next Earnings Date
2025-02-17
Name
Latest SEC Filings
Name
CORT's Discussions on Twitter

Compare CORT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CORT
Corcept Therapeutics Inc
73.96 9.31B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.79 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.46 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.63 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
796.92 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.10 36.88B 4.56B -176.77M 225.30M -1.7177

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-06-23 Upgrade Truist Hold → Buy
Apr-11-23 Initiated SVB Securities Market Perform
Apr-04-23 Initiated Piper Sandler Overweight
Feb-15-23 Downgrade Jefferies Buy → Hold
Aug-01-22 Downgrade Truist Buy → Hold
Jul-27-22 Upgrade Jefferies Hold → Buy
Jun-27-22 Resumed Canaccord Genuity Buy
Feb-02-22 Initiated Canaccord Genuity Buy
Jan-28-22 Initiated Truist Buy
Aug-05-20 Downgrade Jefferies Buy → Hold
Sep-24-19 Initiated Jefferies Buy
Sep-06-19 Initiated H.C. Wainwright Buy
Feb-04-19 Downgrade B. Riley FBR Buy → Neutral
Aug-10-18 Reiterated Stifel Hold
May-31-18 Downgrade Stifel Buy → Hold
Mar-09-18 Initiated B. Riley FBR, Inc. Buy
Aug-31-17 Initiated Stifel Buy
Feb-02-17 Initiated Ladenburg Thalmann Buy
Apr-21-15 Initiated FBR Capital Outperform
Jan-13-14 Downgrade Stifel Buy → Hold
Aug-09-13 Downgrade Janney Buy → Neutral
Aug-09-13 Downgrade Ladenburg Thalmann Buy → Neutral
Feb-21-12 Reiterated JMP Securities Mkt Outperform
Jan-06-10 Upgrade Ladenburg Thalmann Neutral → Buy
Jul-17-08 Initiated Rodman & Renshaw Mkt Outperform
Jun-21-07 Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
View All

Corcept Therapeutics Inc Stock (CORT) Latest News

pulisher
Oct 10, 2025

Corcept Therapeutics (CORT) Sees Significant Drop of 13.3% - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Why Corcept (CORT) Shares Are Falling Today - The Globe and Mail

Oct 10, 2025
pulisher
Oct 10, 2025

Corcept Therapeutics (CORT) Shares Drop as Optime Care Ends Dist - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Corcept Therapeutics (CORT) Adjusts Korlym Distribution Strategy - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

How sentiment analysis helps forecast Corcept Therapeutics Incorporated2025 Retail Activity & Real-Time Volume Triggers - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Corcept Therapeutics (CORT) Shares Drop Amid Market Activity - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Analyzing Corcept Therapeutics Incorporated with risk reward ratio chartsQuarterly Market Summary & Community Consensus Trade Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Corcept Therapeutics (CORT) Rating Reiterated as 'Buy' by HC Wai - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Volume spikes in Corcept Therapeutics Incorporated stock – what they meanJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Corcept Therapeutics' (CORT) "Hold (C)" Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 09, 2025

Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight - The Malaysian Reserve

Oct 09, 2025
pulisher
Oct 09, 2025

Corcept Therapeutics Incorporated stock trend outlook and recovery pathWeekly Profit Recap & Daily Volume Surge Signals - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 4.9%Here's Why - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Pre-ESMO insights: Corcept on platinum-resistant ovarian cancer - pharmaphorum

Oct 08, 2025
pulisher
Oct 07, 2025

Corcept Therapeutics Board Member Resigns, Continues as Consultant - The Globe and Mail

Oct 07, 2025
pulisher
Oct 07, 2025

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Genmab (GMAB) - The Globe and Mail

Oct 07, 2025
pulisher
Oct 07, 2025

Corcept's NDA for its hypercortisolism treatment gets FDA nod - MSN

Oct 07, 2025
pulisher
Oct 07, 2025

1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm - The Globe and Mail

Oct 07, 2025
pulisher
Oct 06, 2025

Myasthenia Gravis Pipeline Outlook Report 2025: Novel Therapeutics, Clinical Advancements, and Opportunities - The Globe and Mail

Oct 06, 2025
pulisher
Oct 06, 2025

'This isn't a dress rehearsal': Why the coming months could be big for a Peninsula drug company that has survived decadesSan Francisco Business Times - The Business Journals

Oct 06, 2025
pulisher
Oct 06, 2025

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135 - 富途牛牛

Oct 06, 2025
pulisher
Oct 06, 2025

What Fibonacci levels say about Corcept Therapeutics Incorporated reboundWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Corcept Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Is a relief rally coming for Corcept Therapeutics Incorporated holdersJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

QRG Capital Management Inc. Acquires 13,829 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Why Corcept Therapeutics Incorporated stock is seen as undervalued2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Visual analytics tools that track Corcept Therapeutics Incorporated performance2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Is Corcept Therapeutics Incorporated (HTD) stock undervalued by metricsJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Earnings Tell The Story For Corcept Therapeutics Incorporated (NASDAQ:CORT) As Its Stock Soars 27% - 富途牛牛

Oct 05, 2025
pulisher
Oct 05, 2025

JSF Financial LLC Makes New Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat

Oct 05, 2025
pulisher
Oct 04, 2025

Corcept Therapeutics (CORT): Evaluating Valuation After New Curant Health Partnership and Pipeline Progress - Yahoo Finance

Oct 04, 2025
pulisher
Oct 03, 2025

Corcept Therapeutics (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 5,000 Shares - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Low-Volatility Stocks Underperforming: RSI, ADT, CORT AnalysisNews and Statistics - IndexBox

Oct 03, 2025
pulisher
Oct 03, 2025

Here’s What Makes Corcept Therapeutics (CORT) an Attractive Investment? - Yahoo Finance

Oct 03, 2025
pulisher
Oct 03, 2025

Synergy Asset Management LLC Raises Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Corcept Therapeutics (NASDAQ:CORT) Downgraded by Zacks Research to Strong Sell - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Public Employees Retirement System of Ohio Boosts Stock Holdings in Corcept Therapeutics Incorporated $CORT - Defense World

Oct 03, 2025
pulisher
Oct 03, 2025

Will Corcept Therapeutics Incorporated (HTD) stock see insider accumulationJuly 2025 Update & Community Supported Trade Ideas - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Wealth Enhancement Advisory Services LLC Buys 5,693 Shares of Corcept Therapeutics Incorporated $CORT - Defense World

Oct 02, 2025
pulisher
Oct 01, 2025

Why Corcept (CORT) Stock Is Trading Up Today - TradingView

Oct 01, 2025
pulisher
Oct 01, 2025

Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym? - Yahoo

Oct 01, 2025
pulisher
Oct 01, 2025

How moving averages guide Corcept Therapeutics Incorporated trading2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - newser.com

Oct 01, 2025
pulisher
Oct 01, 2025

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics - Business Wire

Oct 01, 2025
pulisher
Oct 01, 2025

Published on: 2025-10-01 03:29:23 - newser.com

Oct 01, 2025

Corcept Therapeutics Inc Stock (CORT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Corcept Therapeutics Inc Stock (CORT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Guyer William
Chief Development Officer
Oct 07 '25
Option Exercise
21.65
20,000
433,000
25,287
Guyer William
Chief Development Officer
Oct 07 '25
Sale
89.94
20,000
1,798,782
5,287
$21.35
price down icon 5.74%
$83.80
price down icon 1.12%
$31.81
price down icon 0.13%
$102.06
price down icon 2.32%
$162.33
price down icon 1.26%
biotechnology ONC
$320.10
price down icon 4.68%
Cap:     |  Volume (24h):